{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:36:21Z","timestamp":1789590981607,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,10,12]],"date-time":"2005-10-12T00:00:00Z","timestamp":1129075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:p>A substantial body of animal data indicates that transmissible spongiform encephalopathies (TSEs) are transmitted through blood. These data have been augmented in the past year by reports that two recipients of red cells from donors with variant Creutzfeldt\u2013Jakob disease (vCJD) in the United Kingdom have acquired this infection. Most of the blood donations collected in countries affected by bovine spongiform encephalopathy (BSE) and vCJD also contribute plasma to fractionation pools. Thus, a number of batches of fractionated products have included plasma from donors who developed vCJD. On the basis of public health strategies influenced, in part, by risk assessments, the UK and the French authorities have instituted measures for recalling products and informing patients of the estimated risks. It is therefore relevant to review the principles used by authorities in generating risk assessments for the transmission of TSEs by blood and blood products. While the general principles are fairly straightforward, the final assessments are very dependent on the magnitude of several key parameters, which are, largely, still unknown. A critical determinant of final product risk is the extent to which the plasma fractionation process will contribute to eliminating the infectious prion agent. Therefore, regulatory and industry measures to characterize fractionation processes for their capacity to eliminate prions are to be strongly encouraged. In the interim, an understanding of the principles used to generate risk assessments should contribute to an enhanced ability to address this threat to patient safety. Authorities should recognize that adequate communication is an integral part of good risk\u2010management practices.<\/jats:p>","DOI":"10.1111\/j.1423-0410.2005.00702.x","type":"journal-article","created":{"date-parts":[[2005,10,12]],"date-time":"2005-10-12T15:22:46Z","timestamp":1129130566000},"page":"186-192","source":"Crossref","is-referenced-by-count":17,"title":["Variant Creutzfeldt\u2013Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty"],"prefix":"10.1111","volume":"89","author":[{"given":"A.","family":"Farrugia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Ironside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Giangrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,10,12]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00268.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0041-1132.2003.00586.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00216.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2003.08.004"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-11-2897"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1580"},{"key":"e_1_2_7_10_2","volume-title":"Risk Management Reports.","author":"Kloman F","year":"2003"},{"key":"e_1_2_7_11_2","volume-title":"Efficient Risk Management.","author":"FDA","year":"2003"},{"key":"e_1_2_7_12_2","volume-title":"vCJD Donor Deferral Measures","author":"Farrugia A","year":"2001"},{"key":"e_1_2_7_13_2","volume-title":"Guidance for Industry \u2013 Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt\u2010Jakob Disease (CJD) and Variant Creutzfeldt\u2010Jakob Disease (Vcjd) by Blood and Blood Products.","author":"Center for Biologics Evaluation and Research","year":"2002"},{"key":"e_1_2_7_14_2","volume-title":"Community has Spoken: The Demand for Open Communication Before, During, and After Public Health Emergencies. Program and Abstracts of the American Public Health Association 132nd Annual Meeting","author":"Jenkins TB","year":"2004"},{"key":"e_1_2_7_15_2","volume-title":"Risk Assessment of Exposure to vCJD Infectivity in Blood and Blood Products.","author":"Det Norske Veritas","year":"2003"},{"key":"e_1_2_7_16_2","volume-title":"Variant Creutzfeldt\u2010Jakob Disease (vCJD) and Plasma Products \u2013 Clinical Information.","author":"Health Protection Agency","year":"2004"},{"key":"e_1_2_7_17_2","volume-title":"Variant Creutzfeldt\u2010Jakob Disease (vCJD) and Plasma Products \u2013 Summary of Notification Exercise.","author":"Health Protection Agency","year":"2004"},{"key":"e_1_2_7_18_2","volume-title":"Risk Communication \u2013 Gaps in Communication. Presented to the US Health and Human Services Advisory Committee on Blood Safety and Availability.","author":"Skinner M","year":"2005"},{"key":"e_1_2_7_19_2","volume-title":"Variant Creutzfeldt\u2010Jakob Disease (vCJD): Minimising the Risk of Transmission.","author":"Campbell H","year":"1999"},{"key":"e_1_2_7_20_2","volume-title":"Risk Analysis of New Variant Creutzfeldt\u2010Jakob Disease Transmission by Blood and Blood products.","author":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9 (Afssaps)","year":"2000"},{"key":"e_1_2_7_21_2","volume-title":"Communication from the Commission on the Precautionary Principle.","author":"European Commission","year":"2000"},{"key":"e_1_2_7_22_2","unstructured":"AndersonS: Risk analysis for TSE and plasma products. Presented at the Transmissible Spongiform Encephalopathy Advisory Committee of the Food and Drug Administration 20 February 2003.http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/slides\/3923S1_11.pptandhttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/transcripts\/3923t1.htm"},{"key":"e_1_2_7_23_2","volume-title":"Variant Creutzfeldt\u2010Jakob Disease and Hemophilia \u2013 Further Guidance on Assessing the Risks of Plasma\u2010Derived Products for Treating Hemophilia.","author":"Farrugia A","year":"2004"},{"key":"e_1_2_7_24_2","volume-title":"Management of Possible Axposure to CJD Through Medical Procedures","author":"UK CJD Incidents Panel","year":"2004"},{"key":"e_1_2_7_25_2","volume-title":"Draft Risk Assessment: Potential Exposure to the vCJD agent in United States Recipients of Factor XI Coagulation Product Manufactured in the United Kingdom.","author":"TSE Advisory Committee","year":"2005"},{"key":"e_1_2_7_26_2","volume-title":"A Cursory Analysis Addressing the Question of the Assessment of Exposure to Particular Batches of Variant Creutzfeldt\u2010Jakob Disease (vCJD) Implicated Factor XI Plasma Product.","author":"Public Health Agency of Canada","year":"2005"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2004.0017"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05128-4"},{"key":"e_1_2_7_29_2","volume-title":"CPMP Position Statement on Creutzfeldt\u2010Jakob Disease and Plasma\u2010Derived and Urine\u2010Derived Medicinal Products.","author":"European Medicines Agency","year":"2004"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111169.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-6892.2004.00444.x"},{"key":"e_1_2_7_32_2","volume-title":"Removal of Infectious Prions from Red Cell Concentrates.","author":"Baker H","year":"2005"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998408999.x"},{"key":"e_1_2_7_34_2","unstructured":"Reference 21 Slide 11"},{"key":"e_1_2_7_35_2","unstructured":"Reference 19 p14Table 1"},{"key":"e_1_2_7_36_2","volume-title":"Report of the working party on the supply and use of Factor VIII and Factor IX in Australia","author":"Australian Health Ministers\u2019 Advisory Council Blood and Blood Products Committee","year":"2003"},{"key":"e_1_2_7_37_2","unstructured":"Reference 21 slide 24"},{"key":"e_1_2_7_38_2","unstructured":"Treasury Board of the Canadian Government: Integrated Risk Management Framework.Canadian Government 2001. http:\/\/www.tbs\u2010sct.gc.ca\/pubs_pol\/dcgpubs\/riskmanagement\/dwnld\/rmf\u2010cgr_e.rtf (last accessed 9 September 2005)"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1423-0410.2005.00702.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1423-0410.2005.00702.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T22:21:28Z","timestamp":1696890088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1423-0410.2005.00702.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1423-0410.2005.00702.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1423-0410.2005.00702.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,12]]}}}